Predicting diabetes after kidney transplant study
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This study looks for factors that may help predict who will develop diabetes after a kidney transplant. It is for people who have not had diabetes before their transplant and are starting on tacrolimus and steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have kidney failure that needs a transplant.
- You will receive a kidney from a living or deceased donor.
- You have never had diabetes (type 1 or type 2) before your transplant.
- You are not taking a GLP-1 weight loss medicine (like Ozempic) at the time of the study.
- You are only getting a kidney, not multiple organs, and your donor is compatible (ABO compatible).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medication called an SGLT2 inhibitor can help prevent new-onset diabetes after a kidney transplant. It is for people who have received a kidney transplant, do not have diabetes, and are taking tacrolimus.
This study checks whether using a continuous glucose monitor (a sensor that tracks sugar throughout the day) is helpful and practical for people with a recent kidney transplant and type 2 diabetes on insulin. You may need to wear the sensor continuously and still do finger-stick glucose checks for safety.
This trial tests two diabetes medications, empagliflozin and linagliptin, to see which one works better for controlling blood sugar, protecting kidney function, and improving body composition in people who have had a kidney transplant and have diabetes.
This study looks at tiny molecules called microRNAs to predict if new diabetes might develop after a kidney transplant. By measuring these molecules in your blood, researchers hope to catch early signs and improve care.
This study helps doctors predict who may develop complications from diabetes that appears after a kidney transplant. By understanding your individual risk, your care team can better prevent problems and keep your transplanted kidney healthy longer.
This study looks at how the anti-rejection drug tacrolimus (specifically Envarsus) affects blood sugar and risk of diabetes in kidney transplant patients. It aims to find out which patients might be more likely to develop glucose problems so doctors can adjust treatment early.
Hear when a new Post Transplant Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.